Virus Specific Immune Responses after Human Neoadjuvant Adenovirus-mediated Suicide Gene Therapy for Prostate Cancer
- 31 July 2005
- journal article
- clinical trial
- Published by Elsevier in European Urology
- Vol. 48 (1) , 153-161
- https://doi.org/10.1016/j.eururo.2005.02.013
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Management of high-risk localized prostate cancer: the integration of local and systemic therapy approachesUrologic Oncology: Seminars and Original Investigations, 2003
- Adjuvant and neoadjuvant therapy in prostate cancerSeminars in Oncology, 2001
- Analysis of recent trends in prostate cancer incidence and mortalityThe Prostate, 2000
- In Situ Gene Therapy for Adenocarcinoma of the Prostate: A Phase I Clinical TrialHuman Gene Therapy, 1999
- Cooperative therapeutic effects of androgen ablation and adenovirus-mediated herpes simplex virus thymidine kinase gene and ganciclovir therapy in experimental prostate cancerCancer Gene Therapy, 1999
- Sensitivity and reproducibility in adenoviral infectious titer determinationNature Medicine, 1997
- Adenovirus-mediated herpes simplex virus thymidine kinase gene and ganciclovir therapy leads to systemic activity against spontaneous and induced metastasis in an orthotopic mouse model of prostate cancerInternational Journal of Cancer, 1997
- Prostate Cancer Gene Therapy: Herpes Simplex Virus Thymidine Kinase Gene Transduction Followed by Ganciclovir in Mouse and Human Prostate Cancer ModelsHuman Gene Therapy, 1996
- Follow-up Prostate Cancer Treatments After Radical Prostatectomy: a Population-Based StudyJNCI Journal of the National Cancer Institute, 1996
- Gene therapy for brain tumors: regression of experimental gliomas by adenovirus-mediated gene transfer in vivo.Proceedings of the National Academy of Sciences, 1994